EPIC PEP, 2022 NCT05047601
nirmatrelvir / ritonavir (Paxlovid) (n=2634) vs. placebo (n=-9)
randomized controlled trial
risk of bias NA
Paxlovid for five days followed by placebo for 5 days or paxlovid for ten days
Nirmatrelvir/ritonavir
placebo
3 arms : Paxlovid for 5 days followed by placebo for 5 days or Paxlovid for 10 days or Placebo for 10 days
COVID-19 prophylaxis (excluding children)
double blind